Pellegrini W, Facchetti F, Marocolo D, Salvi L, Capucci A, Tironi A, Rossi G
Department of Pathology, University of Brescia, Italy.
Histopathology. 1995 Nov;27(5):397-405. doi: 10.1111/j.1365-2559.1995.tb00302.x.
The proliferative activity of the haematopoietic and plasma cells in bone marrow was evaluated under normal and neoplastic conditions, by means of a sequential double immunostaining technique, using monoclonal antibody MIB-1 recognizing the cell proliferation-associated nuclear antigen Ki-67, and antibodies against glycophorin-C, myeloperoxidase, factor VIII-related antigen, and immunoglobulin light chains. Fifty-eight B5 fixed, paraffin-embedded bone marrow biopsies were analysed, including 11 normal controls. 10 cases of myelodysplasia, 14 cases of chronic myeloproliferative disorder, eight cases of acute non-lymphoid leukaemia, and 15 cases of myeloma. In normal marrows, the highest proliferative activity was noticed in the erythroid cells (75% to 95%; mean 90%), in comparison with myeloid precursors (15% to 80%; mean 38%), and megakaryocytes (10% to 20%; mean 14%): no Ki-67 positive plasma cells were found. In all investigated haematological disorders, the expression of MIB-1 by erythroid cells was similar to that observed in controls. Similarly, the percentage of MIB-1 + myeloid precursors in chronic myeloproliferative disorders and myelodysplasia largely overlapped the values observed in normals, and comparable values were also found in the blast cells from acute non-lymphoid leukaemia type M1 and M2. These findings suggest that the evaluation of either erythroid or myeloid proliferative activity is of little value in the differential diagnosis between these myeloproliferative disorders. By contrast, the obvious increase of Ki-67 expression of megakaryocytes in chronic myeloproliferative disorders, with labelling also of micro-megakaryocytes, might sustain the diagnosis in controversial cases. Since cases of mature myeloma showed less than 2% of Ki-67 positive cells, evaluation of proliferative activity is of no value in the differential diagnosis with reactive plasmacytosis. The sequential double immunophenotyping for Ki-67 antigen and for haematopoietic cell lineage-associated markers can be applied in a consistent manner to routine bone marrow biopsies to evaluate proliferating cells in normal and neoplastic conditions.
采用序贯双重免疫染色技术,使用识别细胞增殖相关核抗原Ki-67的单克隆抗体MIB-1以及抗血型糖蛋白-C、髓过氧化物酶、因子VIII相关抗原和免疫球蛋白轻链的抗体,对正常和肿瘤状态下骨髓中的造血细胞和浆细胞的增殖活性进行了评估。分析了58例B5固定、石蜡包埋的骨髓活检标本,包括11例正常对照、10例骨髓增生异常综合征、14例慢性骨髓增殖性疾病、8例急性非淋巴细胞白血病和15例骨髓瘤。在正常骨髓中,红系细胞的增殖活性最高(75%至95%;平均90%),相比之下,髓系前体细胞为(15%至80%;平均38%),巨核细胞为(10%至20%;平均14%):未发现Ki-67阳性浆细胞。在所有研究的血液系统疾病中,红系细胞中MIB-1的表达与对照组相似。同样,慢性骨髓增殖性疾病和骨髓增生异常综合征中MIB-1+髓系前体细胞的百分比与正常情况下观察到的值有很大重叠,在M1和M2型急性非淋巴细胞白血病的原始细胞中也发现了类似的值。这些发现表明,评估红系或髓系增殖活性在这些骨髓增殖性疾病的鉴别诊断中价值不大。相比之下,慢性骨髓增殖性疾病中巨核细胞Ki-67表达明显增加,且微巨核细胞也有标记,这可能有助于在有争议的病例中做出诊断。由于成熟骨髓瘤病例中Ki-67阳性细胞少于2%,因此评估增殖活性在与反应性浆细胞增多症的鉴别诊断中无价值。对Ki-67抗原和造血细胞系相关标志物进行序贯双重免疫表型分析可一致应用于常规骨髓活检,以评估正常和肿瘤状态下的增殖细胞。